RIGL
Rigel Pharmaceuticals Inc
$1.36
Earnings Summary
Revenue | $12.62Mn |
Net Profits | $-17.6Mn |
Net Profit Margins | -139.4% |
Highlights
Rigel Pharmaceuticals Inc’s revenue jumped +Inf% since last year same period to $12.62Mn in the Q1 2019. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -66.65% fall in its revenue since last 3-months.
Rigel Pharmaceuticals Inc’s net profit jumped 27.83% since last year same period to $-17.6Mn in the Q1 2019. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -645.17% fall in its net profits since last 3-months.
Rigel Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -139.4% in the Q1 2019. On a quarterly growth basis, Rigel Pharmaceuticals Inc has generated -1734.85% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Rigel Pharmaceuticals Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Current Year | -0.14 |
Highlights
Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a -7.69% fall from last quarter’s estimates.
Rigel Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.14.
Key Ratios
Key ratios of the Rigel Pharmaceuticals Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.24 |
Return on Equity (ROE) | -6.99 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rigel Pharmaceuticals Inc’s return on assets (ROA) stands at -0.24.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rigel Pharmaceuticals Inc’s return on equity (ROE) stands at -6.99.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-03-06 | -0.13 | -0.18 | -38.46% |
2017-05-02 | -0.12 | -0.13 | -8.33% |
2017-08-01 | -0.15 | -0.16 | -6.67% |
2017-11-07 | -0.15 | -0.14 | 6.67% |
Company Information
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
Organisation | Rigel Pharmaceuticals Inc |
Headquarters | 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080 |
Employees | 155 |
Industry | Health Technology |
CEO | Raul Rodriguez |
